S-(+)-besifloxacin | 141388-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: S-(+)-besifloxacin
• 英文别名: (3S)-Besifloxacin；7-[(3S)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
• CAS: 141388-77-4
• 化学式: C₁₉H₂₁ClFN₃O₃
• 分子量: 393.845
• InChiKey: QFFGVLORLPOAEC-JTQLQIEISA-N

物化性质

• 沸点：
  607.0±55.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  S-(+)-besifloxacin 、 11-[(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyl]oxyundecanoic acid 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以65%的产率得到7-[(3S)-3-[11-[(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyl]oxyundecanoylamino]azepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  [EN] TREATMENTS FOR RESISTANT ACNE
  [FR] TRAITEMENTS POUR L'ACNÉ RÉSISTANTE

  摘要：

  公开号：

  WO2015114666A9
• 作为产物：
  描述：

  7-(3-Aminoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 在 1,3-butyl-3-methylimidazole L-tryptophan 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 贝西沙星 、 S-(+)-besifloxacin
  参考文献：
  名称：

  Chiral ionic Liquid-based Vortex-assisted Enantio-separation of S-(+) and R-(-) Besifloxacin and Evaluation of Zeropoint Energy by Two-phase Liquid-liquid Extraction

  摘要：

  Besifloxacin is a fourth-generation fluoroquinolone and shows significant antibacterial properties, which works well against a range of bacteria. Besifloxacin ophthalmic solution is the name of the specific form of this medication used to treat eye infections. The vortex-assisted chiral ionic liquid method was used for the separation of Besifloxacin isomers. S- Besifloxacin shows antibacterial action in clinical trials. The R-isomer, however, has not shown biological properties in clinical testing through different cell line. The current proposed chiral assay method was developed between a racemic mixture and a chiral selector. The analytical databases affirm that 1, 2 dichloroethane is used as a non-aqueous (organic media) solvent and that 1,3-butyl-3-methylimidazole L-tryptophan ([Bmim] [Ltrp]) opted used as a specific chiral ionic liquid. The developed ionic liquid based chital hplc method was successfully applied to separation and purification of isomers of Besifloxacin in during the process industries in bulk drugs.

  DOI：

  10.13005/ojc/400124

文献信息

• Treatments for resistant acne
  申请人：VYOME THERAPEUTICS LIMITED

  公开号：US11045479B2

  公开（公告）日：2021-06-29

  The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

  本公开内容一般涉及用于治疗细菌感染的新型分子、组合物和制剂，更具体地说，涉及具有抗生素耐药性病原体的细菌感染。
• COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR PREVENTING INFECTIONS CAUSED BY ANTIBACTERIAL DRUG-RESISTANT BACTERIA
  申请人：Bausch & Lomb Incorporated

  公开号：EP2136812B1

  公开（公告）日：2013-09-04
• COMPOSITIONS AND METHODS FOR MODULATING ENDOPHTHALMITIS USING FLUOROQUINOLONES
  申请人：Bausch & Lomb Incorporated

  公开号：EP2178535B1

  公开（公告）日：2012-09-19
• Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections Caused by Antibacterial Drug-Resistant Bacteria
  申请人：Tyle Praveen

  公开号：US20080261900A1

  公开（公告）日：2008-10-23

  Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.
• Compositions and Methods for Modulating Inflammation Using Fluoroquinolones
  申请人：Zhang Jinzhong

  公开号：US20080306038A1

  公开（公告）日：2008-12-11

  Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates.